相似文献
1
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Antimicrob Agents Chemother. 2007 Jul;51(7):2625-7. doi: 10.1128/AAC.00107-07. Epub 2007 May 14.
2
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
J Clin Microbiol. 2004 Nov;42(11):4980-7. doi: 10.1128/JCM.42.11.4980-4987.2004.
3
Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Ann Clin Microbiol Antimicrob. 2007 Aug 13;6:7. doi: 10.1186/1476-0711-6-7.
4
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
J Antimicrob Chemother. 2004 Aug;54 Suppl 1:i17-22. doi: 10.1093/jac/dkh312.
5
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 2005 Jun;52(2):129-33. doi: 10.1016/j.diagmicrobio.2004.12.009.
6
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Clin Microbiol Infect. 2010 Jul;16(7):973-8. doi: 10.1111/j.1469-0691.2009.02951.x. Epub 2009 Sep 23.
7
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
8
Macrolide resistance determinants in erythromycin-resistant Streptococcus pneumoniae in Turkey.
Jpn J Infect Dis. 2008 Nov;61(6):490-3.
9
Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Enferm Infecc Microbiol Clin. 2012 Apr;30(4):180-3. doi: 10.1016/j.eimc.2011.10.006. Epub 2012 Feb 24.
10
Molecular characterisation of Hungarian macrolide-resistant Streptococcus pneumoniae isolates, including three highly resistant strains with the mef gene.
Int J Antimicrob Agents. 2005 Jun;25(6):488-95. doi: 10.1016/j.ijantimicag.2005.02.010.
引用本文的文献
1
A 2011-2012 survey of doctors' perceptions of korean guidelines and empirical treatment of community-acquired pneumonia.
Infect Chemother. 2013 Dec;45(4):394-405. doi: 10.3947/ic.2013.45.4.394. Epub 2013 Dec 27.
2
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.
Drug Saf. 2009;32(5):359-78. doi: 10.2165/00002018-200932050-00001.
3
Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.
Clin Pharmacokinet. 2009;48(1):23-38. doi: 10.2165/0003088-200948010-00002.
本文引用的文献
1
Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.
Antimicrob Agents Chemother. 2005 Jul;49(7):2903-13. doi: 10.1128/AAC.49.7.2903-2913.2005.
2
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Clin Infect Dis. 2005 Jan 15;40(2):225-35. doi: 10.1086/426817. Epub 2004 Dec 21.
3
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
J Clin Microbiol. 2004 Nov;42(11):4980-7. doi: 10.1128/JCM.42.11.4980-4987.2004.
4
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.
Antimicrob Agents Chemother. 2004 Sep;48(9):3305-11. doi: 10.1128/AAC.48.9.3305-3311.2004.
5
High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).
Antimicrob Agents Chemother. 2004 Jun;48(6):2101-7. doi: 10.1128/AAC.48.6.2101-2107.2004.
6
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis. 2003 Dec 1;37(11):1405-33. doi: 10.1086/380488. Epub 2003 Nov 3.
7
Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
J Antimicrob Chemother. 2003 Dec;52(6):944-52. doi: 10.1093/jac/dkg465. Epub 2003 Oct 29.
8
Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.
Diagn Microbiol Infect Dis. 2003 Jan;45(1):63-7. doi: 10.1016/s0732-8893(02)00498-4.
9
Resistance among Streptococcus pneumoniae: Implications for drug selection.
Clin Infect Dis. 2002 Jun 15;34(12):1613-20. doi: 10.1086/340400. Epub 2002 May 16.
10
Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep.
Emerg Infect Dis. 2002 Jun;8(6):594-7. doi: 10.3201/eid0806.010275.
Zotero 插件